Sign in
EVMN Stock Price, Chart, Stats & News
Evommune, Inc.
Save
Evommune, Inc. (EVMN) does not currently pay a dividend.
256.22M
Market cap
–
Current P/E
–
Forward P/E
EVMN chart
Fundamentals
Gross margin | 89.32% |
Operating margin | -623.62% |
Pretax margin | -529.77% |
Net margin | -529.77% |
Effective tax rate | – |
ROA | -30.62% |
ROE | 89.72% |
D/E | 0.01x |
Interest coverage ratio | -11581.43x |
EVMN valuation
P/E | – |
P/S | 21.96x |
P/B | 3.40x |
P/CF | -9.15x |
P/FCF | -3.72x |
P/OCF | -9.15x |
PEG | -0.50x |
EV multiple | -4.75x |
About
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Similar securities
Based on sector and market capitalization
Report issue